Marcus Jewell Sells 12,562 Shares of Cellebrite DI (NASDAQ:CLBT) Stock

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) CRO Marcus Jewell sold 12,562 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.24, for a total value of $141,196.88. Following the transaction, the executive directly owned 427,128 shares of the company's stock, valued at approximately $4,800,918.72. The trade was a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Marcus Jewell also recently made the following trade(s):

• On Wednesday, August 12th, Marcus Jewell sold 411 shares of Cellebrite DI stock. The stock was sold at an average price of $16.07, for a total value of $6,604.77.

Cellebrite DI Price Performance

Shares of CLBT opened at $11.49 on Tuesday. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of 52.23, a price-to-earnings-growth ratio of 1.53 and a beta of 1.18. Cellebrite DI Ltd. has a 1 year low of $9.58 and a 1 year high of $19.98. The business's 50 day simple moving average is $14.24 and its 200-day simple moving average is $13.83.

Institutional Inflows and Outflows

---

---

Several large investors have recently modified their holdings of CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its position in Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company's stock valued at $34,000 after acquiring an additional 850 shares during the last quarter. Advisory Services Network LLC purchased a new position in Cellebrite DI during the 3rd quarter valued at about $40,000. CWM LLC lifted its position in shares of Cellebrite DI by 57.0% in the 4th quarter. CWM LLC now owns 2,449 shares of the company's stock worth $44,000 after purchasing an additional 889 shares during the period. Elevation Wealth Partners LLC purchased a new stake in shares of Cellebrite DI in the 2nd quarter worth approximately $44,000. Finally, Vestcor Inc bought a new position in shares of Cellebrite DI during the third quarter valued at approximately $70,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Analysts Set New Price Targets

CLBT has been the subject of a number of recent research reports. Weiss Ratings cut shares of Cellebrite DI from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, August 13th. DA Davidson dropped their price target on Cellebrite DI from $22.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, August 14th. JPMorgan Chase & Co. decreased their price objective on Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating on the stock in a research report on Friday, August 14th. Lake Street Capital lowered their price objective on Cellebrite DI from $21.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, August 14th. Finally, Needham & Company LLC dropped their target price on Cellebrite DI from $15.00 to $12.50 and set a "buy" rating for the company in a report on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $16.70.

Check Out Our Latest Analysis on CLBT

Cellebrite DI Company Profile

(Get Free Report)

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

Read More

• Five stocks we like better than Cellebrite DI
• Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
• Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
• Snowflake Could Be Headed for New Highs Despite Insider Selling
• MongoDB Is Surging—And the Next Catalyst Is Almost Here

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].